Back to news

Vedic Elements Pvt. Ltd Acquires Chinese API Manufacturer Sanmark, Ltd.

2006-06-29 | Dalian

Dalian, China, June 29, 2006 - E. J. McKay & Co., Inc. today announced the acquisition of Chinese API manufacturer Sanmark, Ltd. by India's Vedic Elements Pvt. Ltd. Dalian based Sanmark is one of China's leading producers and distributors of high quality nutritional oils and specialty lipids for the dietary supplement, cosmetic and pharmaceutical industries. Vedic Elements is an international investment company with interests in the pharmaceutical industry.

E. J. McKay acted as exclusive financial advisor to Vedic Elements for the transaction. Mr. James Z. Li, CEO of E. J. McKay, says that he's thrilled E. J. McKay could bring together the experience and capital of one emerging market to the high quality products and expanding market of another in order to supply to both the US and Europe. The transaction comes during a time when consumers are becoming increasingly health conscious and are looking for alternative ways to supplement their diets and lifestyles.


Established in 1996, Sanmark Limited holds its headquarters in the Northeast coastal city of Dalian, China. Sanmark specializes in producing lipids with essential fatty acids that are exported to the US and European countries to make dietary supplements, pharmaceuticals and other such products. Sanmark particularly specializes in bulk and organic nutritional oils, such as flaxseed oil and pumpkin seed oil, and concentrated specialty lipids. An industry leader in its sector, Sanmark is a member of the Chinese Oil and Fat Association and a member of the American Oil Chemists' Society (AOCS).


Vedic Elements is an international investment company with a focus in the pharmaceutical industry, specializing in nutritional herbal products for joint-care, memory-enhancement, diabetes, men's and women's health, respiratory support, weight and cholesterol management and other related products. Vedic's interest in the industry stems from its close working relationships with large pharmaceutical conglomerate.